6Sipila K,Koivistoinen T,Moilanen L,et al.Metabolic syndrome and arterial stiffness:the Health 2000 Survey[J].Metabolism,2007,56(3):320-326.
7Tomiyama H,Hirayama Y,Hashimoto H,et al.The effects of changes in the metabolic syndrome detection status on arterial stiffening:a prospective study[J].Hypertens Res,2006,29 (9):673-678.
8Rehman A,Ismail SB,Naing L,et al.Reduction in arterial stiffness with angiotensin Ⅱ antagonism and converting enzyme inhibition a comparative study among Malay hypertensive subjects with a known genetic profile[J].Am J Hypertens,2007,20(2):184-189.
4Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease.Gastroenterology, 2002, 123: 1705-1725.
5Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology, 2004, 39: 476-483.
6Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med,2000, 132: 112-117.
7Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol, 2002, 17:1098-1105.
8Reaven GM,Chen Y-DI.Insulin resistance, its consequences, and coronary heart disease: must we choose a culprit[J].Circulation,1996,93:1780-1783.
9Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans sites and mechanisms[J].Circulation,2002,105:576-582.
10Cohn JN. Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making[J].Am J Hypertens,2001,14:258S-263S.
